7 min. Read

Livongo’s IPO anniversary. DTx pipelines.

Issue 062.

Get E&O weekly. | Subscribe

Digital health research from Brian Dolan.

Welcome to E&O.

Last week I wrote about two UnitedHealth acquisitions, Bristol Myers Squibb's DTx timeline, and UHG's multiple mulligans in digital diabetes. Here's what's happening this week:

  • HHS re-re-confirmed yesterday that we are still in a public health emergency because of COVID--19, and this third declaration will also stay in effect for at least yet another 90 days.
  • Bristol Myers Squibb emailed me last week after the newsletter went out. They asked me to remove the launch timeline for their multiple myeloma digital therapeutic. I found that timeline (Q3 2020 launch) on a (somewhat) blinded job posting for the project, while similar job postings explicitly from BMS didn't provide as many details. BMS said their recruiting firm made a mistake and posted an inaccurate timeline, but wouldn't share the

Paying Subscribers Only

It's a good one, too.
This digital health research is for paying Exits & Outcomes subscribers only. Subscribe now to read this article, get the weekly newsletter, and receive unrestricted access to past and future research from the Exits & Outcomes archives. Smash the link above or below to subscribe yourself -- or head over to our pricing page to subscribe your team or your whole company!

Full access to E&O's research and newsletters.

Get the subscribers-only newsletters + research reports + databases
UnitedHealth’s employee benefits. Omada signals IPO. Detailed Spring Health pricing.
9 min. Read
CMS weighs HCPCS for Natural Cycles, Leva, and Tyto. Plus: Akili Q3 results.
8 min. Read
Lyra Health pricing. Spring Health signals IPO.
6 min. Read
metaMe Health seeks buyer by year-end. CMS offers up digital therapeutics nothingburger
6 min. Read
PDT Pipeline changes. Kinsa shuts down. Trials
5 min. Read
CPT decisions. Trials: Big Health, Mahana and more
6 min. Read
Teladoc quietly bought MSK startup. Omada hits 1M milestone.
5 min. Read
Akili CEO steps down. Aetna rolls back some virtual care coverage
5 min. Read
Biogen cuts digital, MedRhythms, Apple. Pfizer on PDTs.
6 min. Read
CMS: PDTs have potential. Trials: Big, Koko, GAIA
6 min. Read
  • First
  • Previous
  • 1 of 35
  • Next
  • Last